Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists Nuevolution in connection with Amgen’s cash offer
Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

May 22, 2019 Capital Markets and Public M&A

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge advises Umia Sweden and other owners in connection with the sale of Umia Stockholm to Sandbäckens

 Umia Stockholm AB was founded in 2016 by Jonas Hedlund, Rolf Danielsson, Ronnie Ketola and Göran Karlsson, and currently has around 60 employees and a turnover of SEK 190 million (2023). The company specialises in electricity, which accounts for 70 % of its business, and ventilation. As part of the acquisition, Umia Stockholm AB will be integrated into the Sandbäckens brand in the near future.
December 11, 2024

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

 Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.
December 10, 2024

Vinge has assisted Boliden in the acquisition of the Neves-Corvo and Zinkgruvan mines from Lundin Mining

Boliden has entered into a definitive agreement with Lundin Mining to acquire the Neves-Corvo mine in Portugal and the Zinkgruvan mine in Sweden. The upfront cash consideration for the entities is USD 1,300 m plus contingent payments that can reach up to USD 150 m, on a cash and debt-free basis. The transaction, that considerably strengthens Boliden's mine production as well as internal zinc and copper concentrate supply, is subject to customary regulatory approvals.
December 10, 2024